The Clinical Value of Systemic Immune Inflammation Index (SII) in Predicting the Severity of Hospitalized Children...

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children.
• Assessing MPP severity is crucial for timely and appropriate clinical management.
• Novel biomarkers are needed to accurately predict MPP severity.

Purpose of the Study:

• To investigate the efficacy of the Systemic Immune Inflammation Index (SII) as a biomarker for predicting severe MPP in pediatric patients.
• To compare the predictive performance of SII against other inflammatory markers like NLR, PLR, and SIRI.

Main Methods:

• A cohort of 304 hospitalized children with MPP was analyzed, categorized into severe (SMPP) and non-severe groups.
• Univariate and multivariate logistic regression analyses were performed.
• Receiver operating characteristic (ROC) curves were utilized to evaluate the predictive accuracy of SII, NLR, PLR, and SIRI.

Main Results:

• The Systemic Immune Inflammation Index (SII) showed a high area under the curve (AUC=0.940) for predicting severe MPP, with a sensitivity of 0.876 and specificity of 0.987 at a threshold of 699.00.
• SII demonstrated significantly superior predictive value compared to neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune response index (SIRI).
• Multivariate logistic regression identified SII as a significant risk factor for distinguishing severe from non-severe MPP.

Conclusions:

• The Systemic Immune Inflammation Index (SII) is a promising and effective biomarker for predicting the severity of Mycoplasma pneumoniae pneumonia in children.
• SII offers improved sensitivity and specificity over NLR, PLR, and SIRI in evaluating MPP severity.
• Clinical application of SII can aid in risk stratification and management of pediatric MPP cases.